A
Anastasia Wyce
Researcher at GlaxoSmithKline
Publications - Â 12
Citations - Â 652
Anastasia Wyce is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: BET inhibitor & Cancer. The author has an hindex of 7, co-authored 12 publications receiving 482 citations. Previous affiliations of Anastasia Wyce include Pfizer.
Papers
More filters
Journal ArticleDOI
Bet Inhibition Silences Expression of Mycn and Bcl2 and Induces Cytotoxicity in Neuroblastoma Tumor Models.
Anastasia Wyce,Gopinath Ganji,Kimberly N. Smitheman,Chun-wa Chung,Susan Korenchuk,Yuchen Bai,Olena Barbash,BaoChau Le,Peter D. Craggs,Michael T. McCabe,Karen M. Kennedy-Wilson,Lydia V. Sanchez,Romain Luc Marie Gosmini,Nigel J. Parr,Charles F. McHugh,Dashyant Dhanak,Rab K. Prinjha,Kurt R. Auger,Peter J. Tummino +18 more
TL;DR: Evidence is provided for potent BET inhibitor activity in neuroblastoma, a pediatric solid tumor associated with a high frequency of MYCN amplifications, and a role of BET inhibition in apoptosis, signaling, and N-Myc-driven pathways, including the direct suppression of BCL2 and MYCN is suggested.
Journal ArticleDOI
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
Anastasia Wyce,Yan Degenhardt,Yuchen Bai,BaoChau Le,Susan Korenchuk,Ming-Chih Crouthamel,Charles F. McHugh,Robert L. Vessella,Caretha L. Creasy,Peter J. Tummino,Olena Barbash +10 more
TL;DR: I-BET762 potently reduced MYC expression in prostate cancer cell lines and a patient-derived tumor model with subsequent inhibition of cell growth and reduction of tumor burden in vivo, suggesting that I-Bet762 effects are partially driven by MYC down-regulation.
Journal ArticleDOI
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina Anne Piha-Paul,Christine L. Hann,Christopher A. French,Sophie Cousin,Irene Brana,P. A. Cassier,Victor Moreno,Johann S. de Bono,Sara Duckworth Harward,Geraldine Ferron-Brady,Olena Barbash,Anastasia Wyce,Yuehui Wu,Thierry Horner,Meg Annan,Nigel J. Parr,Rabinder K Prinjha,Christopher L. Carpenter,John Hilton,David S. Hong,Naomi B. Haas,Mark C. Markowski,Arindam Dhar,Peter J. O'Dwyer,Geoffrey I. Shapiro,Geoffrey I. Shapiro +25 more
TL;DR: Once-daily molibresib was tolerated at doses demonstrating target engagement in patients with nuclear protein in testis (NUT) carcinoma (NC), and preliminary data indicate proof-of-concept in NC.
Journal ArticleDOI
Research Resource: The androgen receptor modulates expression of genes with critical roles in muscle development and function.
TL;DR: New insights are provided into the mechanisms by which androgens promote muscle growth and validate AR as a potential therapeutic target for sarcopenia, muscle wasting, and other androgen-related muscle disorders.
Journal ArticleDOI
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Anastasia Wyce,Jeanne J. Matteo,Shawn W. Foley,Daniel J. Felitsky,Satyajit R. Rajapurkar,Xi-Ping Zhang,Melissa C. Musso,Susan Korenchuk,Natalie Karpinich,Kathryn Keenan,Melissa Stern,Lijoy K. Mathew,Charles F. McHugh,Michael T. McCabe,Peter J. Tummino,Peter J. Tummino,Ryan G. Kruger,Christopher L. Carpenter,Olena Barbash +18 more
TL;DR: Investigating the biomarkers of activity of the clinical BET inhibitor GSK525762 across cancer cell lines and demonstrating that KRAS mutations are novel resistance biomarkers highlight a potential to enhance the clinical benefit of BET and MEK inhibitors and provide a strong rationale for clinical evaluation of BET/MEK combination therapies in cancer.